Search

Displaying results 1081 - 1090 of 10000 in total
  1. Drug

    Pimozide

    go.drugbank.com/drugs/DB01100
    Approved

    A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome.

    Categories: Dopamine D2 Receptor AntagonistsProducts: NOROFREN 2 MG TABLET, 20 ADET, NOROFREN 2 MG TABLET, 500 ADET
  2. Drug

    Rifampin

    go.drugbank.com/drugs/DB01045
    ApprovedInvestigational

    Rifampin, also known as rifampicin, is a broad-spectrum antimicrobial [A263748] that was first discovered in 1965 [A263753] and clinically used in 1968.

    Mixtures: RIFAMPICINA 300 MG + ISONIAZIDA 150 MG, RIFAMPICINA 300 MG + ISONIAZIDA 150 MGSynonyms: 5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate
  3. Drug

    Dolutegravir

    go.drugbank.com/drugs/DB08930
    ApprovedInvestigational

    [L1035] On November 21, 2017, dolutegravir, in combination with rilpivirine, was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named … [A31342] Dolutegravir was developed by ViiV Healthcare and FDA-approved on August 12, 2013.

    Mixtures: TRIUMEQ® 50 MG / 600 MG / 300 MG, TRIUMEQ 50 MG/600 MG/300 MG FILM KAPLI TABLET,90 FILM KAPLI TABLETCategories: Antivirals used in combination for the treatment of HIV infections
  4. Drug

    Mirtazapine

    go.drugbank.com/drugs/DB00370
    ApprovedInvestigational

    [A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. … Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994.

    Products: MIRTAZAPINA EG, MIRTAZAPINA EG STADA
  5. Drug

    Cabozantinib

    go.drugbank.com/drugs/DB08875
    ApprovedInvestigational

    [L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 … Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor.

    Products: CABOMETYX 20 MG FİLM KAPLI TABLET, 30 ADET, CABOMETYX 40 MG FİLM KAPLI TABLET, 30 ADET
  6. Drug

    Vilazodone

    go.drugbank.com/drugs/DB06684
    ApprovedInvestigational

    Vilazodone was given FDA approval on January 21, 2011[L6046,A177622].

    Products: ZİLADONE 20 MG FİLM KAPLI TABLET, 30 ADET, ZİLADONE 10 MG FİLM KAPLI TABLET, 30 ADET
  7. Drug

    Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB10598
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Synonyms: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
  8. Drug

    Influenza A virus A/California/7/2009 (H1N1) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10773
    ApprovedInvestigationalWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Synonyms: Influenza A virus A/California/7/2009 (H1N1) recombinant hemagglutinin antigen
  9. Drug

    Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB14619
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Synonyms: Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
  10. Drug

    Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB14620
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Synonyms: Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)